To further evaluate the impact of PPARδ on the patients’ survival, we searched a large cohort of GC patients in the Kaplan–Meier Plotter public database [23] and found that PPARδ mRNA expression levels measured with a specific PPARδ probe (208044_s_at) were negatively associated with the GC patients’ OS and PFS: among the 875 evaluated GC patients, those with low PPARδ mRNA expression had longer median OS (89.4 months [n = 318]) and PFS (32.4 months [n = 363]) than those with high PPARδ mRNA expression (OS: 23.5 months [n = 557] and PFS: 12.2 months [n = 277]) (Fig. 1a, b). The gene discussed is PPARD; the disease is gastric cancer.